# Telix Pharmaceuticals

Source: https://nuclide.cc/companies/telix/  
Nuclide record `telix` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline.

## Summary

Telix Pharmaceuticals, based in Melbourne and listed as TLX.AX, is the Australian theranostics company behind the Illuccix and Gozellix kits for gallium-68 PSMA-11 imaging and a broad therapeutic pipeline. TLX250-CDx, or zirconium-89 girentuximab for carbonic anhydrase IX PET in kidney cancer, received an FDA complete response letter in 2025, TLX591, or lutetium-177 rosopatamab, a PSMA antibody in the ProstACT phase 3, and TLX101 for glioma follow. Nuclide links it to prostate cancer and renal cell carcinoma, to PSMA as a target, to CAIX PET and PET tracer manufacturing, and to the idea of CAIX theranostics pairing girentuximab imaging with lutetium or actinium therapy. Whether an antibody-based PSMA therapy can compete with small-molecule ligands is the open question. Illuccix has its own page.

Its lung-cancer position is entirely pre-clinical, which is worth stating plainly because the company is often named in the same breath as lung radiopharmaceuticals. No asset on the published pipeline carries a lung indication, and ClinicalTrials.gov returns no recruiting Telix lung-cancer study. What exists is two commitments. In January 2025 Telix bought a pipeline of early-stage therapeutic candidates and a biologics platform from ImaginAb for US$45 million plus up to US$185 million in milestones, including a discovery-stage programme against DLL3, the surface protein of small-cell lung cancer, with no TLX code or isotope assigned. In April 2026 it signed a collaboration with Regeneron covering four initial programmes built on Regeneron antibodies, for US$40 million upfront, an equal share of costs and profits and up to US$2.1 billion in milestones; Telix’s own second-quarter 2026 results describe that collaboration as initially focused on lung cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Melbourne
- Type: radiopharma
- Website: https://telixpharma.com
- Ticker: TLX.AX

## Sources

- Official website: https://telixpharma.com
- Telix and Regeneron announce strategic radiopharma collaboration (13 April 2026): https://telixpharma.com/news-views/telix-and-regeneron-announce-strategic-radiopharma-collaboration/
- Telix Q2 2026 results: the Regeneron collaboration is "initially focused on lung cancer" (21 July 2026): https://telixpharma.com/news-views/telix-q2-2026-revenue-us247m-strong-momentum-and-pipeline-progress/
- Telix asset purchase from ImaginAb, including a discovery-stage DLL3 programme for small-cell lung cancer (13 January 2025): https://www.sec.gov/Archives/edgar/data/2007191/000200719125000003/frelease.htm
- Telix pipeline (no lung indication listed): https://telixpharma.com/our-pipeline/

## Connected records

- indications: [Non-small cell lung cancer](https://nuclide.cc/indications/nsclc/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Renal cell carcinoma](https://nuclide.cc/indications/rcc/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)
- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Zirconium-89](https://nuclide.cc/isotopes/zr-89/)
- targets: [CAIX (carbonic anhydrase IX)](https://nuclide.cc/targets/caix/), [DLL3](https://nuclide.cc/targets/dll3/), [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Floretyrosine F-18 (FET)](https://nuclide.cc/drugs/f-18-fet/), [Gallium-68 gozetotide (PSMA-11)](https://nuclide.cc/drugs/ga68-psma-11/), [Illuccix (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/illuccix/), [Lutetium-177 rosopatamab tetraxetan](https://nuclide.cc/drugs/tlx-591/), [Zirconium-89 girentuximab](https://nuclide.cc/drugs/girentuximab-zr89/)
- trials: [89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study](https://nuclide.cc/trials/nct06750419/), [PSMA PET Combined With MRI for the Detection of PCa](https://nuclide.cc/trials/nct07052214/), [The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)](https://nuclide.cc/trials/nct06520345/), [ZIRCON](https://nuclide.cc/trials/zircon/)
- technologies: [CAIX PET (89Zr-girentuximab)](https://nuclide.cc/technologies/caix-pet/), [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://nuclide.cc/technologies/cyclotron-isotope-production/), [PET tracer manufacturing and distribution](https://nuclide.cc/technologies/pet-tracer-manufacturing/), [Radionuclide generators and cold kits](https://nuclide.cc/technologies/radionuclide-generators-kits/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/)
- ideas: [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://nuclide.cc/ideas/idea-caix-theranostics/)
- bottlenecks: [Reimbursement and coding for radiopharmaceuticals](https://nuclide.cc/bottlenecks/b-reimbursement-coding/)
- fronts: [Molecular imaging](https://nuclide.cc/fronts/f-molecular-imaging/), [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/)
- key papers: [ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma](https://nuclide.cc/key-papers/paper-zircon-lancet-oncol-2024/)

---
JSON: https://nuclide.cc/api/v1/entities/telix.json